本文選題：靶向治療 + 卵巢腫瘤�。� 參考：《中國(guó)實(shí)用婦科與產(chǎn)科雜志》2015年03期

【摘要】：卵巢癌復(fù)發(fā)率高,預(yù)后差,多數(shù)患者在反復(fù)間斷化療后最終都會(huì)出現(xiàn)耐藥。近年來(lái)靶向藥物在復(fù)發(fā)性耐藥性卵巢癌的臨床試驗(yàn)中取得了較為可喜的結(jié)果。廣泛研究的靶向藥物有血管內(nèi)皮生長(zhǎng)因子受體抑制劑如貝伐單抗,DNA損傷修復(fù)抑制劑如奧拉帕尼、Veliparib,血管生成素抑制劑如Trebananib,葉酸受體抑制劑如Vintafolide等等。近期研究顯示,這些藥物可延長(zhǎng)鉑耐藥卵巢癌患者的無(wú)疾病間期。其中貝伐單抗聯(lián)合單藥化療是目前臨床應(yīng)用較為成熟的治療方案。文章重點(diǎn)介紹靶向治療在復(fù)發(fā)性耐藥性卵巢癌臨床研究中的最新進(jìn)展。
[Abstract]:The recurrence rate of ovarian cancer is high and the prognosis is poor. Most patients will eventually develop drug resistance after repeated intermittent chemotherapy. In recent years, targeted drugs have achieved gratifying results in clinical trials of relapsed ovarian cancer. Widely studied targeted drugs include vascular endothelial growth factor receptor inhibitors such as bevacizumab DNA damage repair inhibitors such as olapanil Veliparibb angiopoietin inhibitors such as Trebananib folic acid receptor inhibitors such as Vintafolide and so on. Recent studies have shown that these drugs prolong the disease-free interval in patients with platinum-resistant ovarian cancer. Among them, bevacizumab combined with single drug chemotherapy is a mature clinical treatment. This article focuses on the latest progress of targeted therapy in the clinical study of recurrent ovarian cancer with drug resistance.
【作者單位】： 中國(guó)醫(yī)學(xué)科學(xué)院腫瘤醫(yī)院;
【分類號(hào)】：R737.31

【共引文獻(xiàn)】

相關(guān)期刊論文 前10條

1 王彥潔;李小平;楊欣;;卵巢上皮性腫瘤腹水的治療現(xiàn)狀及進(jìn)展[J];中國(guó)婦產(chǎn)科臨床雜志;2014年02期

2 曾靖;張蓉;;白蛋白結(jié)合型紫杉醇在婦科腫瘤中的研究進(jìn)展[J];國(guó)際婦產(chǎn)科學(xué)雜志;2014年03期

3 路慧s，

本文編號(hào)：1916329